Manufacturing of a product in 2018 is increased by 20% than previous year while its selling is decreased by 8% from the previous year. If unsold products in 2018 is 414 more than that in 2017 and only 5% of manufactured products in 2017 remains unsold, then how many products are sold in 2018?

Manufacturing of a product in 2018 is increased by 20% than previous year while its selling is decreased by 8% from the previous year. If unsold products in 2018 is 414 more than that in 2017 and only 5% of manufactured products in 2017 remains unsold, then how many products are sold in 2018? Correct Answer 1311

Let the manufactured product in 2017 and 2018 is ‘100x’ and ‘120x’ respectively.

Sold products in 2017 = 95% of 100x = 95x

Unsold products in 2017 = 100x – 95x = 5x

Sold products in 2018 = 92% of 95x = 87.4x

Unsold products in 2018 = 120x – 87.4x = 32.6x

According to the question ∶

32.6x – 5x = 414

x = 15

Sold products in 2018 = 87.4x = 1311

Related Questions

In the question below, are given a statement followed by three courses of actions numbered I, II and III. On the basis of the information given, you have to assume everything in the statement to be true, and then decide which of the suggested courses of action logically follow(s) for pursuing. Statement: India’s pharmaceutical sector is now popping out from a shell and making a remarkable recovery. Actually, it has been facing several regulatory challenges in the forms of a recast of foreign direct investment (FDI) policy, pricing policy in the US generics market, patent protection, regulatory approvals and compulsory licensing. Also limited new product launches in the generics space, GST introduction and higher costs associated with regulatory compliance have hurt the sector. Courses of action: I. The government has been engrossed more in policy making and taking resilient decisions for the concerns of the pharma industry. Recently, the government proposed to introduce a new price index for pharmaceutical products, which would serve as a benchmark for determining prices of all medicines sold in the country. II. Meanwhile, pharma companies’ constant investments in R&D have enabled them to develop a basket of robust products for markets across the world. In international markets, pricing pressure on generics sold in the US has eased and this is likely to support the sector. III. Domestic pharma sales grew to Rs. 10,583 crore in May 2018 from Rs. 9,549 crore in the same month last year. The recent clearance by the US Food and Drug Administration to Sun Pharma’s manufacturing plant at Halol in Gujarat brings to an end a two-year import ban it had imposed on the company over quality issues. This is likely to increase sales for the company.